Medifast Announces New CEO and Leadership Transition
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
The latest announcement is out from Medifast ( (MED) ).
On May 19, 2026, Medifast stockholders re-elected all seven directors to the board, ratified RSM US LLP as independent auditor for 2026, and approved on an advisory basis the compensation of its named executive officers. Investors also approved amendments to the company’s 2012 share incentive plan, reinforcing Medifast’s ability to use equity-based compensation to attract and retain senior talent and align management incentives with shareholder interests.
On May 26, 2026, Medifast announced that Nick Johnson will become chief executive officer effective June 8, 2026, succeeding Daniel R. Chard, who will transition to non-executive chairman. Johnson’s total target compensation will rise by 69%, with a $600,000 base salary and an increased long-term incentive opportunity, underscoring the board’s confidence in his leadership as the company pursues its growth strategy and seeks to strengthen its position in the health and wellness market.
The most recent analyst rating on (MED) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Medifast stock, see the MED Stock Forecast page.
Spark’s Take on MED Stock
According to Spark, TipRanks’ AI Analyst, MED is a Neutral.
The score is held down primarily by deteriorated fundamentals—declining revenue, ongoing losses, and negative free cash flow—despite a strong balance sheet. Technicals are supportive with the stock trading above key moving averages, but momentum is getting near overbought. The latest earnings call adds some stabilization signals (sequential revenue uptick, productivity gains, cost actions, strong liquidity), though guidance still implies continued losses and execution risk.
To see Spark’s full report on MED stock, click here.
More about Medifast
Medifast is a health and wellness company focused on weight management and metabolic health solutions, primarily offering meal replacement products and structured nutrition programs. The company targets consumers seeking clinically supported approaches to weight loss and long-term wellbeing, working through both direct-to-consumer channels and a network of independent coaches.
Average Trading Volume: 230,754
Technical Sentiment Signal: Sell
Current Market Cap: $140M
Learn more about MED stock on TipRanks’ Stock Analysis page.
